Date: 1 July 2016
Tarceva® (erlotinib) is no longer indicated for the first-line maintenance treatment in patients without an epidermal growth factor receptor (EGFR)-activating mutation based on data from the IUNO study. The results of the IUNO study led to the conclusion that the benefit-risk of Tarceva® is no longer considered favourable for maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after 4 cycles of standard platinum-based first-line chemotherapy whose tumours do not harbour an EGFR-activating mutation. Please refer to the DHPC issued by Roche (Malaysia) Sdn. Bhd. for further information.